James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Are Casino Stocks Really This Untouchable?

Casino stocks have been obliterated left and right in the past few months. But the pain might be partly undeserved, which means bargains could be afoot.

Sizzling Small Caps: Can They Keep It Up?

Get the scoop on these three small cap picks to find out if they will be able to keep up their hot streaks.

Before You Assume the Worst for Vivus …

While there are many reasons to be pessimistic about the future of pharma stock Vivus, the research that has fueled its recent drop is not one of them.

The 3 Dirtiest Words in Investing

These three terms are used and abused all the time when it comes to company accounting. Find out what they could be hiding.

Is It Time to Sell Abbott Labs?

Abbott Labs has been on a tear since October, but its technical strength is wearing thin, plus a few other factors stand to hamper this otherwise solid company.

Surprise! ‘Cheap’ Chinese Labor Isn’t So Cheap Anymore

Many American companies are starting to be weighed down by what used to be a boon -- Chinese labor costs. And some already are making moves out.

Will Vivus Repeat Arena’s Non-Response?

Two days don't make or break a stock, but Vivus' response to Qsymia's approval is far from encouraging. The time to buy might be long past.

Standout Stocks in a Packed Tobacco Field

No one contests that these are difficult times to peddle tobacco products. But like all industries, some stocks are healthier than others.

Merck Could Have a Home Run in Sight

Merck’s new drug odanacatib can be thanked for the stock's recent rally, but there are two questions that need to be answered.

The Market Is Walking on the Edge of a Cliff

The market is in a good news/bad news situation, with the scales tipped toward bad. If the S&P's technical floor breaks, things could get ugly in a hurry.